Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Liver Neoplasms 1Liver Cirrhosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 938Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
epigallocatechin gallate × Gastrointestinal × Clear all
NCT06015022 2025-09-05

CATCH-B

University of Texas Southwestern Medical Center

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms

NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06398405 2024-05-03

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Shandong Cancer Hospital and Institute

Phase 2 Unknown
72 enrolled
Gastrointestinal

Deglutition Disorders, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡